NASDAQ:KYMR Kymera Therapeutics (KYMR) Stock Price, News & Analysis $35.28 +0.73 (+2.11%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$35.33 +0.05 (+0.13%) As of 05/2/2025 04:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Kymera Therapeutics Stock (NASDAQ:KYMR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Kymera Therapeutics alerts:Sign Up Key Stats Today's Range$33.95▼$35.9850-Day Range$21.05▼$35.3852-Week Range$19.45▼$53.27Volume640,377 shsAverage Volume556,422 shsMarket Capitalization$2.29 billionP/E RatioN/ADividend YieldN/APrice Target$56.36Consensus RatingModerate Buy Company OverviewKymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Read More… Kymera Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks41st Percentile Overall ScoreKYMR MarketRank™: Kymera Therapeutics scored higher than 41% of companies evaluated by MarketBeat, and ranked 822nd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingKymera Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.87, and is based on 11 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageKymera Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Kymera Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Kymera Therapeutics are expected to decrease in the coming year, from ($2.79) to ($3.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kymera Therapeutics is -15.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kymera Therapeutics is -15.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKymera Therapeutics has a P/B Ratio of 4.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Kymera Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.52% of the float of Kymera Therapeutics has been sold short.Short Interest Ratio / Days to CoverKymera Therapeutics has a short interest ratio ("days to cover") of 10.5, which indicates bearish sentiment.Change versus previous monthShort interest in Kymera Therapeutics has recently decreased by 7.76%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKymera Therapeutics does not currently pay a dividend.Dividend GrowthKymera Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted13.52% of the float of Kymera Therapeutics has been sold short.Short Interest Ratio / Days to CoverKymera Therapeutics has a short interest ratio ("days to cover") of 10.5, which indicates bearish sentiment.Change versus previous monthShort interest in Kymera Therapeutics has recently decreased by 7.76%, indicating that investor sentiment is improving significantly. News and Social Media3.0 / 5News Sentiment1.44 News SentimentKymera Therapeutics has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.83 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Kymera Therapeutics this week, compared to 5 articles on an average week. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Kymera Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $324,567.00 in company stock.Percentage Held by Insiders15.82% of the stock of Kymera Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Kymera Therapeutics' insider trading history. Receive KYMR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kymera Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address KYMR Stock News HeadlinesWhy Kymera Therapeutics Stock Crushed it This WeekApril 25, 2025 | fool.comKymera Therapeutics to unveil new oral development candidateApril 25, 2025 | markets.businessinsider.comBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time is about to validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.May 3, 2025 | Golden Portfolio (Ad)Kymera Therapeutics Advances KT-621 Clinical Trials in Atopic Dermatitis and AsthmaApril 23, 2025 | nasdaq.comKymera Therapeutics announces first patient dosed in BROADEN Phase 1b trialApril 23, 2025 | markets.businessinsider.comKymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 DegraderApril 22, 2025 | globenewswire.comKymera Therapeutics appoints Goodman as Chief Business OfficerApril 9, 2025 | msn.comKymera Therapeutics Appoints Noah Goodman as Chief Business OfficerApril 9, 2025 | globenewswire.comSee More Headlines KYMR Stock Analysis - Frequently Asked Questions How have KYMR shares performed this year? Kymera Therapeutics' stock was trading at $40.23 at the beginning of 2025. Since then, KYMR shares have decreased by 12.3% and is now trading at $35.28. View the best growth stocks for 2025 here. How were Kymera Therapeutics' earnings last quarter? Kymera Therapeutics, Inc. (NASDAQ:KYMR) posted its earnings results on Thursday, February, 27th. The company reported ($0.88) earnings per share for the quarter, missing analysts' consensus estimates of ($0.76) by $0.12. The business earned $7.39 million during the quarter, compared to analysts' expectations of $14.81 million. Kymera Therapeutics had a negative trailing twelve-month return on equity of 24.96% and a negative net margin of 191.26%. Read the conference call transcript. When did Kymera Therapeutics IPO? Kymera Therapeutics (KYMR) raised $126 million in an IPO on Friday, August 21st 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, BofA Securities, Cowen and Guggenheim Securities acted as the underwriters for the IPO. Who are Kymera Therapeutics' major shareholders? Kymera Therapeutics' top institutional shareholders include Massachusetts Financial Services Co. MA (0.65%), Rhumbline Advisers (0.11%), Harbor Capital Advisors Inc. (0.05%) and Victory Capital Management Inc. (0.02%). Insiders that own company stock include Venture Fund X LP Atlas, Bvf Partners L P/Il, Bruce Booth, Bruce N Jacobs, Jared Gollob, Ellen Chiniara, Jeremy G Chadwick, Joanna Horobin and Jeffrey W Albers. View institutional ownership trends. How do I buy shares of Kymera Therapeutics? Shares of KYMR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Kymera Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kymera Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Tesla (TSLA), JPMorgan Chase & Co. (JPM) and First Solar (FSLR). Company Calendar Last Earnings2/27/2025Today5/03/2025Next Earnings (Estimated)5/09/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KYMR CIK1815442 Webwww.kymeratx.com Phone857-285-5300FaxN/AEmployees170Year FoundedN/APrice Target and Rating Average Stock Price Target$56.36 High Stock Price Target$74.00 Low Stock Price Target$36.00 Potential Upside/Downside+59.7%Consensus RatingModerate Buy Rating Score (0-4)2.87 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)($2.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-146,960,000.00 Net Margins-191.26% Pretax Margin-191.26% Return on Equity-24.96% Return on Assets-20.27% Debt Debt-to-Equity RatioN/A Current Ratio8.55 Quick Ratio8.55 Sales & Book Value Annual Sales$47.07 million Price / Sales48.67 Cash FlowN/A Price / Cash FlowN/A Book Value$7.12 per share Price / Book4.96Miscellaneous Outstanding Shares64,944,000Free Float54,519,000Market Cap$2.29 billion OptionableOptionable Beta2.22 These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:KYMR) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredReal Americans Don’t Wait on Wall Street’s Next MoveWhat's happening in the markets right now should concern every freedom-loving American who's worked hard and s...Premier Gold Co | SponsoredThe collapse has already startedThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kymera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kymera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.